Genmab sells Arzerra co-promotion option for $4.5 million
This article was originally published in Scrip
Executive Summary
Genmab is selling its co-promotion option for Arzerra (ofatumumab) for $4.5 million, losing co-promotion rights to the anticancer in the US and Nordic region.